ClinicalTrials.gg
CompletedNCT00787891Updated Jan 24, 2013Results posted

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

A Phase 3 interventional study of rabeprazole and rabeprazole in Gastroesophageal Reflux Disease (GERD), sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2013-01-24.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
18th of 39
127 · median 100
Started
2009
with 3 others
Phase 3
16 of 40
none open now
Registered
26th of 40
by date
Lead sponsor
4 of 40
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 18th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 16 in phase 3, and was the 26th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).

Read the detailed description

This is a randomized, double-blind study that consists of two parts. In Part 1, the study will consist of 3 phases: a 14-day screening phase, a double-blind treatment phase of 12 weeks comparing two doses of study drug (0.5 mg/kg or 1.0 mg/kg groups based on patient's body weight), and an end-of-study or early withdrawal phase followed by Part 2, which consists a of double-blind treatment continuation for patients who have achieved healing during the short-term double-blind treatment phase. The double-blind maintenance treatment phase lasts for not more than 24 weeks and is concluded by an end-of-study/early withdrawal visit. During Part 1, patients will be screened and the diagnosis of erosive and non-erosive Gastroesophageal Reflux Disease (GERD) will be made based on clinical symptoms and confirmed by endoscopy/histology after a biopsy. Patients enrolled in the study will receive study drug once daily for 12 weeks. Each day, the parent/caregiver will record the presence and severity of pre-specified GERD symptoms. At Weeks 4 and 8, the investigator will evaluate the response to treatment by assessment of the GERD symptoms. At Week 12, the investigator will perform an endoscopy of the esophagus with a biopsy to confirm that histological healing has occurred. If a patient continues, additional study drug will be dispensed (at the same dose taken during the short-term double-blind treatment phase) and the patient will be scheduled to return every 8 weeks until study drug is discontinued at Week 24 (Part 2) of the double-blind maintenance treatment phase. At the final visit of the maintenance treatment phase Week 24 (Part 2), assessments including an endoscopy of the esophagus with a biopsy be performed for each patient. Assessments of effectiveness include endoscopic and histological grading of biopsy samples, GERD symptom and severity score (symptoms and severity rated daily by the parent/caregiver in an electronic diary), overall GERD symptom relief, Clinical Global Impression of Improvement (CGI-I) score, and the Global Treatment Satisfaction Score. Safety assessments will include the monitoring of concomitant therapies and adverse events throughout the study, clinical laboratory testing (including hematology, clinical chemistry, urinalysis), vital signs, and physical examination including height, weight, and Tanner staging. Oral rabeprazole 2.5 capsules or 5 mg capsules, given once daily at a dose of 0.5 mg/kg or 1.0 mg/kg; short-term treatment phase is 12 weeks; long-term maintenance treatment phase is 24 weeks.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • Gastroesophageal Reflux Disease (GERD)
  • Erosive Gastroesophageal Reflux Disease
  • Ulcerative Gastroesophageal Reflux Disease
  • Endoscopy
  • Pediatrics
  • Rabeprazole
04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months of screening
  • Positive esophagogastroduodenoscopy
  • Signed
  • Female patients (if menstruating) must be practicing

Exclusion criteria

Exclusion Criteria:

  • Patients with history of esophagitis
  • Patients who have milk protein allergy
  • Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days
  • Patients who have taken sucralate or any medication that affects gastrointestinal motility
  • Patients with H. pylori
  • Patients with lab values outside the normal age appropriate range
  • Patients who have participated in another trial within 30 days before screening
  • Patients with allergies to Proton Pump Inhibitors
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Rabeprazole 0.5 mg/kg

    rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

    Drug: rabeprazole

  • Experimental
    Rabeprazole 1.0 mg/kg

    rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

    Drug: rabeprazole

Interventions

  • 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

  • 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)

    Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.

    Time frame: 12 weeks

  2. The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)

    Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.

    Time frame: 36 weeks

Secondary outcomes

  1. The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)

    The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.

    Time frame: Baseline, Week 12

  2. The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)

    The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.

    Time frame: Baseline, Week 12

  3. The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)

    The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.

    Time frame: Baseline, Week 36

  4. The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)

    The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.

    Time frame: Baseline, Week 36

07

Results

Posted Oct 11, 2012

Participant flow

Short-term Double-blind Phase (Part 1)
Participant flow — Short-term Double-blind Phase (Part 1)
MilestoneRabeprazole 0.5 mg/kgRabeprazole 1.0 mg/kg
Started6562
Completed5553
Not completed109
Withdrew: Adverse event12
Withdrew: Lost to follow-up22
Withdrew: Protocol violation01
Withdrew: Physician decision10
Withdrew: Withdrawal by subject62
Withdrew: Other02
Maintenance Double-blind Phase (Part 2)
Participant flow — Maintenance Double-blind Phase (Part 2)
MilestoneRabeprazole 0.5 mg/kgRabeprazole 1.0 mg/kg
Started3331
Completed2624
Not completed77
Withdrew: Adverse event01
Withdrew: Non-compliance with study drug11
Withdrew: Withdrawal by subject13
Withdrew: Other52

Outcome measures

PrimaryThe Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)
Percentage of participantsRabeprazole Sodium 0.5 mg/kgRabeprazole Sodium 1.0 mg/kg
The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)78 (67 to 89)83 (73 to 93)
PrimaryThe Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.

Time frame:
36 weeks
Reported as:
Number · Percentage of patients
The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)
Percentage of patientsRabeprazole Sodium 0.5 mg/kgRabeprazole Sodium 1.0 mg/kg
The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)92 (82 to 100)88 (76 to 100)
SecondaryThe Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · Scores on a scale
The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)
Scores on a scaleRabeprazole Sodium 0.5 mg/kgRabeprazole Sodium 1.0 mg/kg
The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)-1.3 ± 0.85-1.0 ± 0.81
SecondaryThe Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · Scores on a scale
The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)
Scores on a scaleRabeprazole Sodium 0.5 mg/kgRabeprazole Sodium 1.0 mg/kg
The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)-11.5 ± 11.70-8.5 ± 9.75
SecondaryThe Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.

Time frame:
Baseline, Week 36
Reported as:
Mean · Scores on a scale
The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)
Scores on a scaleRabeprazole Sodium 0.5 mg/kgRabeprazole Sodium 1.0 mg/kg
The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)0.2 ± 0.490.2 ± 0.54
SecondaryThe Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.

Time frame:
Baseline, Week 36
Reported as:
Mean · Scores on a scale
The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)
Scores on a scaleRabeprazole Sodium 0.5 mg/kgRabeprazole Sodium 1.0 mg/kg
The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)-2.9 ± 4.82-1.4 ± 9.59

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 0.5 mg/kg (Short-term Double-blinde Phase)—5/65 (7.7%)47/65 (72.3%)
Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase)—1/62 (1.6%)47/62 (75.8%)
Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase)—2/33 (6.1%)18/33 (54.5%)
Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase—3/31 (9.7%)21/31 (67.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventRabeprazole 0.5 mg/kg (Short-term Double-blinde Phase)Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase)Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase)Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase
BronchopneumoniaInfections and infestations1/650/620/331/31
LymphadenitisBlood and lymphatic system disorders0/650/620/331/31
Conversion DisorderPsychiatric disorders0/650/620/331/31
Head InjuryInjury, poisoning and procedural complications0/650/621/330/31
Partial Seizures with Secondary GeneralisationNervous system disorders0/650/621/330/31
GastroenteritisInfections and infestations0/651/620/330/31
BronchitisInfections and infestations1/650/620/330/31
Gastrointestinal InfectionInfections and infestations1/650/620/330/31
PneumoniaInfections and infestations1/650/620/330/31
Humerus FractureInjury, poisoning and procedural complications1/650/620/330/31
Most frequent other events
Showing 10 of 124
Most frequent other events
EventRabeprazole 0.5 mg/kg (Short-term Double-blinde Phase)Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase)Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase)Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase
VomitingGastrointestinal disorders8/6510/624/333/31
CoughRespiratory, thoracic and mediastinal disorders9/659/622/330/31
Abdominal PainGastrointestinal disorders7/658/623/332/31
Upper Respiratory Tract InfectionInfections and infestations6/654/624/334/31
PyrexiaGeneral disorders8/655/620/333/31
DiarrhoeaGastrointestinal disorders7/657/621/333/31
HeadacheNervous system disorders4/657/621/330/31
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders2/656/620/332/31
DyspepsiaGastrointestinal disorders1/651/620/332/31
Nasal CongestionRespiratory, thoracic and mediastinal disorders4/651/620/330/31

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rabeprazole 0.5 mg/kgRabeprazole 1.0 mg/kgTotal
<=18 years6562127
Between 18 and 65 years000
>=65 years000
Age Continuous
Age Continuous(years)Rabeprazole 0.5 mg/kgRabeprazole 1.0 mg/kgTotal
Mean5.9 ± 3.495.4 ± 3.265.7 ± 3.37
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 0.5 mg/kgRabeprazole 1.0 mg/kgTotal
Female312556
Male343771
Baseline BMI
Baseline BMI(kg/cm2)Rabeprazole 0.5 mg/kgRabeprazole 1.0 mg/kgTotal
Mean17.5 ± 4.0816.8 ± 3.1117.2 ± 3.64
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Sloan S, Silber S, Leitz G. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013 Dec;57(6):798-807. doi: 10.1097/MPG.0b013e3182a4e718. PubMed 23863328 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 9 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2008
First posted
Nov 10, 2008
Start
Jan 2009
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results delay requested
Jul 6, 2012
Results first posted
Oct 11, 2012
Last update
Jan 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00787891
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Nov 10, 2008
Start date
Jan 2009
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Oct 11, 2012
Last update
Jan 24, 2013

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion